Results 121 to 130 of about 87,198 (263)
ROOT-ExM: Super-Resolution Imaging of Proteins in <i>Arabidopsis</i> Roots by Expansion Microscopy. [PDF]
Shimizu Y +6 more
europepmc +1 more source
P-compressed Quadtrees for Image Storing [PDF]
C. Anedda, Leonardo Felician
openaire +1 more source
The process of internalization of the Shiga toxin A subunit via formation of a complex with the Shiga toxin B subunit, which specifically binds to the Gb3 receptor. The peptide is designed to act as a carrier of drugs into cancer cells. Here, we explored the potential of peptides derived from the catalytic A subunit of Shiga toxin (STxA) to be drug ...
Giulia Opassi +6 more
wiley +1 more source
sc-rDSeq: Droplet-based single-cell full-length total RNA-seq method. [PDF]
Sun X, Ram O.
europepmc +1 more source
Investigating transcription factor dynamics in health and disease using FRAP
FRAP analysis of GFP‐tagged transcription factors reveals how molecular mobility and target engagement change in response to drug treatment. By combining live‐cell imaging, quantitative model fitting, and statistical analysis, this approach uncovers transcription factor dynamics linked to disease mechanisms, providing a powerful framework for ...
Kannan Govindaraj +3 more
wiley +1 more source
Expanding the OMOP common data model to support extracorporeal life support research. [PDF]
Rieder C +16 more
europepmc +1 more source
Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta +3 more
wiley +1 more source
Parallelised Cloning, Mammalian Cell Expression, and Purification of Nanobodies Identified by Phage Display. [PDF]
Campaigne HA +3 more
europepmc +1 more source
Although too much iron in the brain promotes neurodegeneration, iron ion chelators have had mixed effects in clinical trials. This review explains why; some chelators do not render the iron redox‐inactive (e.g., L1) whereas others do (e.g., desferrioxamine).
Barry Halliwell
wiley +1 more source

